HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.

Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard

Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard.

Afiliação

Rinnerthaler G; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg,
Gampenrieder SP; Cancer Cluster Salzburg, 5020 Salzburg, Austria. g.rinnerthaler@salk.at.
Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg,

Int J Mol Sci ; 20(5)2019 Mar 05.

Article em En | MEDLINE | ID: mdl-30841523

Assuntos

Antineoplásicos Imunológicos/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Maitansina/análogos & derivados; Inibidores de Proteínas Quinases/uso terapêutico; Receptor ErbB-2/metabolismo; Trastuzumab/uso terapêutico; Ado-Trastuzumab Emtansina; Ensaios Clínicos como Assunto; Feminino; Humanos; Maitansina/uso terapêutico

Palavras-chave

(vic-)trastuzumab duocarmazine; ADC; HER2 low; HM2-MMAE; TAK-522; Trastuzumab deruxtecan; Trastuzumab emtansine; anti-HER2/PBD-MA; mode of action

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Inibidores de Proteínas Quinases / Trastuzumab / Antineoplásicos Imunológicos / Maitansina Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google